文献速递慢性静脉疾病

VICI静脉支架治疗症状性髂股静脉梗阻的1年可行性研究结果

The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2017-12-28

该可行性研究纳入30例症状性髂股静脉梗阻患者,评估VICI静脉支架的安全性和有效性。12个月一期通畅率93%、二期通畅率100%,85%患者静脉临床严重程度评分改善≥2分,生活质量显著提升。支架无断裂,结论认为安全可行。

要点

  • 12个月一期通畅率93%,二期通畅率100%,无支架断裂。
  • 85%患者VCSS改善≥2分,疼痛和生活质量评分显著改善。
  • 两例支架闭塞均发生于血栓后梗阻患者。

核心结论

  • VICI静脉支架治疗症状性髂股静脉梗阻安全可行,12个月通畅率优良,临床症状和生活质量显著改善。

研究设计与样本

  • 国际多中心医疗器械豁免可行性研究,2014年6月至2015年2月纳入30例患者(24例女性,中位年龄43岁)。
  • 所有患者为单侧髂股静脉疾病,狭窄≥50%,排除3个月内急性深静脉血栓或靶血管既往手术/腔内干预者。

主要发现

  • 病变以血栓后病因为主(63%),左肢与右肢比例5:1,9例(30%)病变延伸至腹股沟韧带下。
  • 中位随访701天;12个月一期、辅助一期和二期通畅率分别为93%、96%和100%。
  • 12个月内两例支架闭塞(发生于19天和385天),均为血栓后梗阻患者;无支架断裂。
  • 12个月时23例(85%)VCSS改善≥2分(中位改善5分),视觉模拟评分中位疼痛减轻20 mm,慢性静脉功能不全问卷评分改善15分。

临床怎么用

  • 对于症状性髂股静脉梗阻,尤其是血栓后病变,可考虑使用VICI静脉支架,预期12个月通畅率高且临床症状改善明显。

局限性

  • 可行性研究样本量小(30例),随访时间有限,结果需 pivotal 阶段(170例,22中心)进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the safety and efficacy of a dedicated venous stent (the VICI VENOUS STENT; VENITI, Fremont, Calif) for treatment of symptomatic iliofemoral venous outflow obstruction. METHODS: Thirty patients (24 female; median age, 43 years) were enrolled in the feasibility phase of an international, multicenter investigational device exemption trial from June 2014 to February 2015. All patients exhibited unilateral venous disease with ≥50% stenosis in the iliofemoral veins. Patients within 3 months of acute deep venous thrombosis or with prior surgical or endovascular intervention of the target vessel were excluded. Lesions were primarily of post-thrombotic causes (63%), with a left limb-right limb ratio of 5:1. Nine patients (30%) had lesions extending beneath the inguinal ligament. Median baseline stenosis was 91%; 11 patients (37%) had occlusions. RESULTS: Fifty-one stents were implanted successfully in 30 patients. Median residual stenosis was 0%, as estimated by venography and intravascular ultrasound. Median follow-up was 701 days. At 12 months, primary, assisted-primary, and secondary patency was 93%, 96%, and 100%, respectively. The stent occluded in two patients through the 12-month window (occurring at 19 and 385 days). Both occlusions occurred in patients presenting with post-thrombotic obstruction. No patients in this cohort exhibited stent fracture at 12 months. Symptomatic improvement of ≥2 points on the Venous Clinical Severity Score was observed in 23 patients (85%) at 12 months (median score improvement, 5 points). There was a median 12-month pain reduction of 20 mm on the visual analog scale score and 15-point improvement on the Chronic Venous Insufficiency Questionnaire score. Scores improved significantly on all three clinical and quality of life scales at 6 and 12 months. CONCLUSIONS: The VICI VENOUS STENT is safe and feasible for treatment of symptomatic iliofemoral venous obstruction, with excellent 12-month patency rates and significant improvement seen in clinical symptoms and quality of life indices. The pivotal phase (170 patients, 22 centers) of this investigational device exemption trial is currently ongoing.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Razavi M, Marston W, Black S, et al. The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 29290601. doi:10.1016/j.jvsv.2017.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。